HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Own-Labeler Lesson, Ingredient-Testing Lapse Noted Again In FDA Warnings

Executive Summary

Sportron International "cannot contract out its ultimate responsibility to ensure that the dietary supplement it places into commerce" is compliant, and Absonutrix failed "to conduct at least one appropriate test or examination to verify the identity of a dietary ingredient," say FDA warning letters listing some of the most frequently noted problems found in GMP and labeling inspections.

You may also be interested in...

US FDA Warns Supplement Own Labeler About Reliance On Manufacturer For Compliance

Revival Products’ GMP deficiencies concerned work and training of its quality control staff, including failing to document review and approval for release of any packaged and labeled supplement for distribution and destroying returned products without review.

No Change On Identity Testing Exemptions: Health, Beauty And Wellness Industry News

Identity testing exemption number unchanged; CRN backs DSM's petition to simplify vitamin naming; UNPA has MOU with China import/export chamber; and USANA sets European expansion openings.

Opposite Sides Of GMP Coin: Contract Manufacturer, Own-Labeler Warned

Contract manufacturer Nutritional Engineering was warned on Sept. 29, 2017, about GMP violations and misbranding problems found during an inspection in April and May. Liberty, Texas, own-labeler Carol Bond Health Foods was warned March 9 following a September inspection of its facility and a November review of its website.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts